Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | EYA2 | O00167 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248146 | 0.86 | MEN1 (0.38) | HDAC6HDAC1HDAC2MEN1GAA | |
| SCHEMBL2435231 | 0.86 | HDAC6 (0.37) | HDAC6HDAC1HDAC2MEN1GAA | |
| SCHEMBL28195146 | 0.83 | MEN1 (0.33) | HDAC6HDAC1HDAC2MEN1GAA | |
| SCHEMBL28195145 | 0.83 | MEN1 (0.33) | HDAC6HDAC1HDAC2MEN1GAA | |
| SCHEMBL10493844 | 0.83 | ALDH1A1 (0.39) | HDAC6HDAC1HDAC2MEN1GAA | |
| SCHEMBL78691 | 0.82 | CA14 (0.41) | HDAC6HDAC1HDAC2MEN1GAA | |
| SCHEMBL336495 | 0.80 | HDAC6 (0.37) | HDAC6HDAC1HDAC2MEN1GAA | |
| SCHEMBL8768722 | 0.80 | HDAC6 (0.39) | HDAC6HDAC1HDAC2MEN1GAA | |
| SCHEMBL2524373 | 0.80 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL12979636 | 0.79 | TET2 (0.38) | HDAC6HDAC1HDAC2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112375015-A | Preparation method of di-tert-butyloxycarbonylaminoacetic acid | 安徽昊帆生物有限公司 | 2021-02-19 | — | — | CN | claimed |
| CN-119970617-A | Improved coupling joint | 普罗林科斯有限责任公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-114286693-A | Improved coupling joint | 普罗林科斯有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-112375015-A | Preparation method of di-tert-butyloxycarbonylaminoacetic acid | 安徽昊帆生物有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-112375015-A | Preparation method of di-tert-butyloxycarbonylaminoacetic acid | 安徽昊帆生物有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-112375015-A | Preparation method of di-tert-butyloxycarbonylaminoacetic acid | 安徽昊帆生物有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20130109681-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-02 | — | — | US | disclosed |
| US-6388061-B1 | INCLUDES RUTHENIUM TRIS(BIPYRIDYL) LABEL BONDED TO THE NITROGEN BASE | DAKO A/S (DK) | 2002-05-14 | — | — | US | disclosed |
| US-5675023-A | VISION DEFECTS; NERVOUS SYSTEM DISORDERS; COMPLICATIONS OF DIABETES | TSUMURA & CO. (JP) | 1997-10-07 | — | — | US | disclosed |
| US-5627204-A | ENZYME INHIBITORS FOR TREATMENT OF DIABETES | TSUMURA & COMPANY (JP) | 1997-05-06 | — | — | US | disclosed |
| US-5455267-A | For reducing side effects of diabetes | TSUMURA & CO. (JP) | 1995-10-03 | — | — | US | disclosed |
| EP-0516860-A1 | CHROMONE DERIVATIVE AND ALDOSE REDUCTASE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1992-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109681-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | HDAC6 1309/4885HDAC1 1054/4885HDAC2 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.